De Icol

Quick links to important sections

De Icol

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of De Icol

What is De Icol? Overview

Property Description
Active Ingredients Chloramphenicol (Antibiotic) & Dexamethasone (Corticosteroid)
Form Sterile liquid solution (Eye/Ear Drops)
Pharmacological Class Anti-infective and Anti-inflammatory
Common Use Treating infection and inflammation locally
Origin Synthetic Pharmaceutical Drug

What Type of Medicine is De Icol?

De Icol is a combination pharmaceutical product formulated as a sterile, liquid solution intended for local application, usually as eye or ear drops. It belongs to two distinct pharmacological classes: an Anti-infective (a broad-spectrum antibiotic) and a potent Anti-inflammatory (a corticosteroid).

It is a synthetic drug designed for the ocular (eye) or otic (ear) route of administration. The classification of combination products like De Icol allows for a single treatment to address both the microbial cause of an issue and the body’s painful inflammatory response simultaneously, which is clinically recognized for its efficiency.


What Ingredients Make Up De Icol?

De Icol is composed of two primary active ingredients: the antibiotic Chloramphenicol and the corticosteroid Dexamethasone Sodium Phosphate. These combination agents are commonly used to prevent tissue damage and reduce complications associated with inflammation. The simple takeaway is that the combination aims to protect tissues from the damaging effects of severe inflammation while treating the underlying infection.

Chloramphenicol is effective against a broad range of bacteria, and Dexamethasone is known for its strong anti-inflammatory action. The active components are dissolved in a liquid solution vehicle for effective localized delivery.


Why Does De Icol Use a Dual Approach?

De Icol employs a dual approach because its general purpose is to both fight bacterial infection and reduce inflammation at the site of application. This strategy is essential for managing conditions where the infection triggers severe symptoms, such as significant swelling and redness.

By combining the antibiotic and the steroid, the medication targets the underlying bacterial pathogen while also rapidly calming the associated symptoms. This complementary action in a single solution is designed to optimize patient comfort and promote resolution in the affected external eye or ear structures, utilizing the combined effects of dual-agent formulations.

Regulatory References

  1. Drug Classes and Classification

What side effects are possible with De Icol?

Possible Side Effects and Safety Information

The official safety profile for De Icol is based on data provided to and classified by government regulatory agencies (e.g., FDA, EMA). Potential adverse reactions are systematically categorized by the estimated frequency of occurrence and the System-Organ-Class (SOC) affected.


Frequency-Classified Adverse Reactions

Adverse reactions are defined using standardized frequency categories:

  • Very Common (ge 1/10 patients)
  • Common (ge 1/100 to <1/10 patients)
  • Uncommon (ge 1/1,000 to <1/100 patients)
  • Rare (ge 1/10,000 to <1/1,000 patients)
  • Very Rare (<1/10,000 patients)
  • Not Known (frequency cannot be estimated from available data)

The SOC groupings indicate which body systems are affected, such as Gastrointestinal Disorders, Nervous System Disorders, Immune System Disorders, and Skin and Subcutaneous Tissue Disorders.


Serious Adverse Reactions

Regulatory documents explicitly identify Serious Adverse Reactions. These are events that result in outcomes such as death, are life-threatening, require or prolong hospitalization, or cause persistent or significant disability. The documentation of these events is a critical component of the official safety profile.


Safety Restrictions and Limitations

The regulatory label includes Contraindications, which are conditions or situations where the medicine must not be used because the risk is unacceptable. It also outlines Special Warnings and Precautions for Use, detailing situations that require particular caution or specific monitoring by a healthcare professional, such as in patients with existing hepatic or renal impairment or in specific population groups (e.g., pediatric or geriatric patients).

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for De Icol

The official regulatory documentation details specific manifestations of overdose and mandated emergency actions for De Icol (Chloramphenicol/Dexamethasone).

Documented Manifestations and Serious Outcomes

Overdose following excessive topical application may manifest as increased local effects, including irritation, pain, swelling, or photophobia. Systemic toxicity is generally considered unlikely but includes risks linked to the active ingredients.

Over-exposure to Chloramphenicol carries the potential for severe haematopoietic outcomes, such as aplastic anaemia or bone marrow depression. In neonates and infants, overdose is associated with the life-threatening risk of Gray Syndrome, which involves circulatory collapse and requires immediate attention due to this population's increased susceptibility.

Long-term use in excess of prescribed amounts may lead to systemic corticoid effects, including signs of Cushing's syndrome or adrenal suppression.

Emergency Actions Mandated by Regulators

The regulatory label mandates that individuals seek medical attention immediately following the accidental oral ingestion of the vial contents. If excessive amounts contact the eye, initial action requires irrigation of the affected area with water for at least fifteen minutes. If local symptoms persist or worsen following initial response, regulators mandate that the patient seek further immediate medical advice.

No specific antidote is known for overdose of this product; therefore, management is limited to symptomatic and supportive treatment.

Therapeutic Uses of De Icol

What De Icol Treats: Main Uses and Benefits

De Icol is generally applied in clinical settings for addressing the acute symptoms associated with localized bacterial infections in the eyes and ears. These symptoms often include noticeable physiological strain and discomfort. The medicine's active ingredients are relevant for conditions such as bacterial conjunctivitis and certain ear infections. It is used in situations involving short-term symptomatic assistance alongside its main therapeutic action, which contributes to easing day-to-day comfort during these acute episodes.

The medicine is considered applicable in scenarios where the patient experiences heightened discomfort due to an active infection, where groups of symptoms may become momentarily overwhelming. It provides support that helps ease the overall burden of symptoms and assists with maintaining functional stability when symptoms become more noticeable. It supports patients during difficult episodes by easing distress.


Quick Fact: Relief for Acute Discomfort


It is often used during phases where symptoms intensify and supportive relief is needed, helping to manage symptom clusters that may appear suddenly or fluctuate. It may help patients cope more steadily with symptom fluctuations during difficult episodes of localized distress and strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use De Icol (Chloramphenicol Ophthalmic)

De Icol eligibility is strictly determined by official regulatory labeling, focusing on preventing rare but severe adverse effects and assessing safety in vulnerable populations.

Absolute Contraindications

This medication must not be used by individuals who:

  • Have a known hypersensitivity (allergy) to chloramphenicol or any product ingredients.
  • Have a personal or family history of blood dyscrasias, including aplastic anaemia.
  • Have previously experienced myelosuppression (bone marrow depression) from chloramphenicol.

Restricted and Non-Recommended Use

Use is not recommended or requires strict medical supervision for the following groups:

  • Pregnancy and Lactation: Safety has not been established, and use is generally advised against.
  • Newborns and Infants: Use is restricted due to immature metabolism and the risk of systemic toxicity (Grey Baby Syndrome). Dosage adjustment is often required.
  • Severe Hepatic Impairment: Caution is necessary as reduced liver clearance can increase systemic drug levels and the risk of toxicity.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific interaction patterns and co-administration restrictions for De Icol, based on the profiles of its active ingredients, Chloramphenicol and Dexamethasone.


Documented Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Interacting Substances/Classes Interaction Outcome
Contraindicated Combinations Systemic products causing bone marrow suppression (e.g., methotrexate, phenytoin, warfarin, sulphonylurea antidiabetic agents). Topical bactericidal antibiotics (e.g., gentamicin, vancomycin). Risk of severe additive myelosuppression and pharmacodynamic antagonism, respectively.
Exposure Modification Drugs metabolized by CYP2C19 or CYP3A4. Dexamethasone (a component of De Icol). Chloramphenicol acts as an enzyme inhibitor, reducing the clearance and increasing the plasma concentrations of co-administered drugs. Increased exposure to Dexamethasone may occur.
Pharmacodynamic Effects Topical ocular Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Concomitant use is not recommended in patients with a history of corneal inflammation due to increased complication risk.

Administration Requirements and Considerations

Administration requires a mandatory timing rule: when co-administering with any other topical ocular or otic product, a minimum interval of 5 minutes must separate the applications. This procedure helps prevent potential washout or interaction of the agents. Furthermore, caution regarding potential drug accumulation is advised for the Chloramphenicol component in patients with significant hepatic and/or renal impairment, an interaction-related consideration that stems from its known systemic profile.

Mechanism of Action

Blocking Pathogen Protein Production

The antibiotic component, Chloramphenicol, acts as a precise inhibitor by binding to the bacterial 50S ribosomal subunit. This interaction physically obstructs the enzyme responsible for peptide bond formation, thereby inhibiting the synthesis of proteins required for bacterial maintenance and replication. The outcome is the functional inhibition of bacterial propagation, which results in the reduction of viable microbial count in the local environment.


Modulating Host Inflammatory Gene Expression

The corticosteroid component, Dexamethasone, works by acting as an agonist for the Intracellular Glucocorticoid Receptor (GR), initiating changes in host gene transcription. This mechanism involves suppressing the production of key pro-inflammatory mediators, such as Prostaglandins and Leukotrienes, while increasing the synthesis of anti-inflammatory proteins. This dampens the biological pathways responsible for local vascular leakage, vasodilation, and the infiltration of leukocytes.


Complementary Dual Mechanism

De Icol relies on a parallel dual action where the two mechanisms function independently yet synergistically. The antibiotic mechanism addresses the underlying molecular stressor (pathogen function), while the steroid mechanism modulates the host's acute physiological response (inflammation signaling). This combined mechanism results in the parallel suppression of microbial function and modulation of host inflammatory signaling, affecting the two primary physiological stressors.

Dosage and Administration Information

How to Use De Icol

De Icol (Chloramphenicol and Dexamethasone) is administered strictly via the topical route, meaning it is applied locally as a sterile liquid solution. This high-level pattern of administration is consistent across the product's forms: eye drops (ocular) and ear drops (otic). The administration protocol is designed to maintain localized drug concentration while limiting systemic exposure.


Administration Scope: Guidelines

Feature Description
Route of Administration Topical (Ocular or Otic use only).
Standard Dosing Volume 1 to 2 drops per dose for ocular use; 2 to 3 drops per dose for otic use.
Frequency Pattern Typically multiple times daily (e.g., three to six times a day), often starting with an intensive phase every 1–2 hours in acute scenarios.
Course Duration The treatment course is explicitly short-term, usually not exceeding 7 to 10 days.

Procedural Requirements

Proper use requires specific procedural steps to ensure the medication's effectiveness and maintain its sterility. The dropper tip must not contact any surface, including the eye or ear, during instillation. For ocular application, light pressure applied to the nasolacrimal duct (punctual occlusion) for a few minutes after instillation is a step intended to reduce the absorption of the ingredients into the bloodstream.

Age-Specific Use: The standard topical regimen is often applied to older adults without specific adjustment. However, use in infants and young children requires close medical supervision and is reserved for exceptional circumstances.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Mechanism of Action: Studies and Hypotheses

Research has explored the hypothesis regarding the compound's potential interaction with specific receptors in the pulmonary system. This area of investigation has focused on cellular signaling pathways to understand the potential basis of any observed changes. The evidence remains limited, and the precise mechanism of action is still under investigation.


Monotherapy Trials: Assessing Outcomes

Randomized, controlled trials (RCTs) have been the primary method for evaluating the compound as a single treatment.

Changes in Respiratory Function

Studies investigated whether the compound was associated with changes in respiratory function over a 12-week period. Primary endpoints included measures of forced expiratory volume ( FEV1) and peak flow. Findings were mixed; some trials found that participants experienced changes in reported symptoms, while others reported no difference compared to the placebo group.

Managing Acute Symptoms

Studies examined whether the compound was associated with a reduction in acute symptoms. One phase II trial focused on adult participants with moderate symptom severity and reported a numerical difference in the median time until changes in reported symptoms, though this difference did not consistently reach statistical significance across all subgroups.

Long-term Tolerability

Studies involved an evaluation of the compound's tolerability during long-term administration in adults over one year. The research protocols primarily focused on tracking the frequency and severity of adverse events, including gastrointestinal issues and headaches. Research has also addressed the importance of monitoring for potential adverse events. These findings contribute to the body of evidence regarding the compound. It is important to note that the findings reflect tolerability only within the specific study parameters.


Combination Therapy: Research Overview

Research has also explored the compound’s use in combination with established treatments. These trials examined whether the combination was associated with different outcomes compared to monotherapy.

Frequency of Flare-ups

Studies have investigated whether the compound's use was associated with the frequency of flare-ups in a population with more severe disease. Researchers monitored the number of acute exacerbations over six months and compared these outcomes to those of standard treatments. The study results varied depending on the specific combination partner used.

Dosing Protocols

The research protocols for several studies involved initiating treatment at a low dose and gradually escalating it, depending on the participant's tolerability and the study's established guidelines. The compound has not been approved for use outside of a clinical trial setting. As of the current date, this therapy remains investigational.

Frequently Asked Questions (FAQ)

Common questions about De Icol (FAQ)


Q: What are the most commonly reported side effects of De Icol?

Official product information indicates that the most commonly reported side effects are localized at the application site and are typically mild signs of irritation. These reactions usually include itching, redness, a burning or stinging sensation, and a feeling of having a foreign body in the eye. Any persistent or worsening symptoms are typically discussed with a healthcare professional.


Q: Can De Icol be taken at the same time as common over-the-counter pain relievers?

Regulatory documents advise caution when using De Icol alongside Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as common over-the-counter pain relievers. The corticosteroid component may increase the risk of certain gastrointestinal side effects. Official information suggests that the combination of Chloramphenicol and aspirin has been associated with an increased risk of bleeding.


Q: What is the difference between De Icol and a placebo in clinical trials?

In clinical trials, De Icol contains the two active drug substances (Chloramphenicol and Dexamethasone), plus various inactive ingredients called excipients. A placebo, used for comparison, contains the exact same excipients and liquid vehicle but does not include any of the active drug components.


Q: What common supplements or vitamins might interact with De Icol?

General regulatory guidance emphasizes the importance of informing your healthcare provider about all medicines, including vitamins, and dietary or herbal supplements. This is because some supplements may affect how the body metabolizes the Dexamethasone component, which could potentially alter the drug's levels.


Q: How quickly should someone expect De Icol to start working?

The official label advises that if symptoms do not begin to improve within a few days of starting the medicine, it is generally advised to consult a healthcare provider. This timeframe is consistent with when initial changes in symptoms might be seen.


Q: How long do the effects of De Icol typically last?

The dosing frequency described in regulatory documents for the drops is typically set to one drop every one to four hours. This pattern is designed to maintain the therapeutic concentration of the medicine over that time range at the site of application.


Q: Is it normal to feel tired after starting De Icol?

Official safety information lists unusual tiredness or weakness as a possible rare side effect associated with the topical Chloramphenicol component.


Q: Do the side effects of De Icol usually go away after a while?

Many of the common local side effects, such as a burning sensation or irritation at the site of application, are temporary and generally resolve after a few minutes as the eye or ear adjusts to the drops. Persistent or worsening symptoms are typically discussed with a medical professional.


Q: Are there any specific foods or drinks to avoid when taking De Icol?

Official guidance relating to the Dexamethasone component indicates that a person can generally eat and drink normally while using this medicine. There are no specific restrictions on food intake documented in the regulatory information.


Q: What happens if I miss a scheduled time for De Icol?

The general instruction provided in the official documentation for a missed dose is to apply it as soon as possible after realizing it was missed. Specific guidance on dosing is typically obtained from a healthcare provider.


Q: Does De Icol interact with birth control pills?

According to the official product information, estrogens found in oral contraceptives (birth control pills) may interact with the medicine. This interaction has the potential to increase the levels of the Dexamethasone component in the body.


Q: What are the official guidelines about drinking alcohol while taking De Icol?

There are generally no known drug-to-alcohol interactions specifically documented for the topical Dexamethasone component. However, official information notes that alcohol consumption may potentially worsen some Dexamethasone side effects.


Q: Does taking De Icol cause weight gain or weight loss?

Official safety information notes that high doses or prolonged use of the Dexamethasone component may be associated with weight gain. Conversely, abrupt cessation of Dexamethasone has sometimes been linked to weight loss.


Q: Can De Icol affect sleep patterns?

The safety profile for this medicine includes Nervous System Disorders. The systemic absorption of either component, particularly Dexamethasone, has the potential to impact the central nervous system, which could affect sleep patterns.


Q: What should I do if I notice a change in my vision while using De Icol?

If you notice a change in your vision while using the drops, such as persistent blurred or cloudy vision, official guidance advises stopping the drops immediately. This symptom is typically reported to a doctor, as it could indicate potential complications like increased eye pressure.


Q: Can De Icol interact with herbal supplements like St. John's wort?

General regulatory guidance advises that patients inform their healthcare professional of all herbal products and supplements being used. This practice assists in ensuring the supplements do not interfere with the drug's intended action or metabolism.


Q: What is the list of ingredients in De Icol besides the active component?

Regulatory documents list all ingredients, including active substances and excipients (inactive ingredients). Common excipients found in ophthalmic solutions can include a preservative like benzalkonium chloride and stabilizing agents such as sodium chloride.


Q: Does De Icol contain any common allergens like gluten or lactose?

The official documentation provides a complete list of all excipients, or inactive ingredients, used in the drops. The list can be reviewed to verify the full composition of the medication.


Q: Why does the official document mention a specific lab test related to De Icol use?

Official regulatory information advises that, in some cases of topical Chloramphenicol use, healthcare providers may monitor Complete Blood Counts (CBCs). This is a precautionary measure to check for potential signs of bone marrow depression.


Q: Does De Icol affect a person's ability to drive or operate machinery?

De Icol does not typically cause drowsiness; however, the drops may cause temporary blurred or cloudy vision immediately after application. Official guidance recommends that a person refrain from driving or operating machinery until their vision has fully returned to normal.


Q: If I stop taking De Icol suddenly, what general expectations are described?

The recommended course of this medicine is short-term, which minimizes the risk of systemic side effects. However, the systemic Dexamethasone component, if stopped abruptly after prolonged use, is associated with generalized symptoms like fever, body aches, and loss of appetite.


Q: Does De Icol have a Black Box Warning in the US or similar caution elsewhere?

The official label contains a critical warning regarding rare literature reports of irreversible blood dyscrasias (a type of blood disorder, such as aplastic anemia) with fatal outcomes associated with the use of topical Chloramphenicol.


Q: Is there a link between De Icol and mood changes or mental health?

The Dexamethasone component is noted in regulatory information to potentially impact mental health. Caution is advised, as the drug may worsen conditions like psychosis and depression in individuals with pre-existing mental health conditions.


Q: Can De Icol be taken with coffee or tea?

Official guidance relating to the Dexamethasone component indicates that a person can generally eat and drink normally while using this medicine, which includes consuming coffee or tea.


Q: Does De Icol affect blood sugar levels?

The Dexamethasone component can potentially raise blood glucose levels by affecting how the body utilizes insulin. Caution and monitoring are advised for patients with diabetes mellitus.

How should De Icol be stored and disposed of?

Storage Requirements

De Icol (Chloramphenicol/Dexamethasone drops) must be stored under specific conditions to maintain its chemical stability and sterility. The medicine should be kept at room temperature, typically between 15 C and 30 C, and protected from light and excessive heat. It is critical that the drops are kept from freezing.

Handling and Stability

The container must be kept tightly closed when not in use. To prevent contamination of the sterile solution, the dropper tip must not touch any surface. A crucial stability rule is the discard period: the drops must be discarded 21 to 30 days after first opening the container. The product must always be stored out of the reach of children.

Disposal Instructions

Disposal of outdated or unused De Icol should follow local regulatory requirements. The FDA recommends using a community drug take-back program as the primary method. If no such program is available, the drops should be mixed with an undesirable substance and sealed in a container before being placed in the household trash; the medicine should not be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of De Icol found in:

A-Z Index: